|1.||Kim, Jerome H: 6 articles (03/2014 - 12/2009)|
|2.||Michael, Nelson L: 6 articles (03/2014 - 12/2009)|
|3.||Pitisuttithum, Punnee: 6 articles (03/2014 - 09/2004)|
|4.||Rerks-Ngarm, Supachai: 5 articles (03/2014 - 12/2009)|
|5.||Nitayaphan, Sorachai: 5 articles (03/2014 - 12/2009)|
|6.||Francis, Donald: 4 articles (03/2014 - 07/2012)|
|7.||Kaewkungwal, Jaranit: 4 articles (03/2014 - 12/2009)|
|8.||Robb, Merlin L: 4 articles (04/2013 - 12/2009)|
|9.||Tartaglia, Jim: 4 articles (04/2013 - 12/2009)|
|10.||Berman, Phillip W: 4 articles (08/2012 - 09/2004)|
08/18/2011 - "The RV144 trial on the ALVAC/AIDSVAX candidate HIV vaccine, carried out in Thailand, showed short-lived protection against infection. "
02/01/2010 - "In 2003, a phase III placebo-controlled trial (VAX004) of a candidate HIV-1 vaccine (AIDSVAX B/B) was completed in 5,403 volunteers at high risk for HIV-1 infection from North America and the Netherlands. "
02/11/2009 - "The first HIV vaccine efficacy trial in the US and Europe VAX004, was designed to assess whether rgp120 envelope subunits (AIDSVAX B/B, VaxGen) can induce partial or complete protection from HIV-1 infection. "
10/01/1998 - "AIDSVAX (VaxGen, Inc., South San Francisco, CA), a possible vaccine to protect against human immunodeficiency virus type 1 (HIV-1) infection, is being tested for efficacy in phase 3 studies. "
05/01/1997 - "Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity."
|2.||HIV Infections (HIV Infection)
09/01/2001 - "The DSMB was scheduled to conduct its review in November 2001, to examine the efficacy of AIDSVAX in the prevention of HIV infection. "
01/01/2010 - "However, the recent RV144 HIV vaccine trial in Thailand showed that a prime/boost immunization strategy involving priming with canarypox vCP1521 followed by boosting with rgp120 could provide significant, although modest, protection from HIV infection. "
02/01/2009 - "Among IDUs in the AIDSVAX B/E trial, incarceration in jail was associated with incident HIV infection. "
01/01/2014 - "Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?"
02/11/2009 - "AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection."
|3.||Acquired Immunodeficiency Syndrome (AIDS)
01/26/2004 - "This report presents the safety and reactogenicity data derived from 11 multicenter, randomized controlled trials of ALVAC-HIV vaccines conducted by the HIV Vaccine Trials Network (HVTN) and its predecessor, the AIDS Vaccine Evaluation Group (AVEG). "
06/01/1999 - "Three-year Phase III AIDS vaccine trials are underway at approximately 50 sites for AIDSVAX, one of the most promising vaccines. "
|5.||Communicable Diseases (Infectious Diseases)
|4.||RNA (Ribonucleic Acid)
|8.||aluminum sulfate (alum)
|9.||Brain Natriuretic Peptide (Natrecor)